Journal Scans
First Line Therapy With Fludarabine Compared to Chlorambucil Does Not Result in a Major Benefit for Elderly Patients With Advanced Chronic Lymphocytic Leukemia
First-Line Fludarabine Not Superior to Chlorambucil in Elderly Patients With CLL
BF Eichhorst, R Busch, S Stilgenbauer, M Stauch, MA Bergmann, M Ritgen, N Kranzhöfer, R Rohrberg, U Söling, O Burkhard, A Westermann, V Goede, CD Schweighofer, K Fischer, A-M Fink, CM Wendtner, G Brittinger, H Döhner, B Emmerich, M Hallek, GCLLSG
20090615
2009 Jul 15
Blood
First Line Therapy With Fludarabine Compared to Chlorambucil Does Not Result in a Major Benefit for Elderly Patients With Advanced Chronic Lymphocytic Leukemia
Blood. 2009 Jul 15; Epub ahead of print, BF Eichhorst, R Busch, S Stilgenbauer, M Stauch, MA Bergmann, M Ritgen, N Kranzhöfer, R Rohrberg, U Söling, O Burkhard, A Westermann, V Goede, CD Schweighofer, K Fischer, A-M Fink, CM Wendtner, G Brittinger, H Döhner, B Emmerich, M Hallek, GCLLSG
Abstract
Abstract
While CLL is a disease of elderly patients, subjects older than 65 years are heavily underrepresented in clinical trials. The German CLL study group (GCLLSG) initiated a multicentre phase III trial for CLL patients older than 65 years comparing first line therapy with fludarabine to chlorambucil. 193 patients with a median age of 70 years were randomized to receive fludarabine (25 mg/m² for 5 days intravenously, every 28 days, for 6 courses) or chlorambucil (0•4 mg/kg body weight with increase...
